Recurrent bacterial infections, but not fungal infections, characterise patients with ELANE-related neutropenia: a French Severe Chronic Neutropenia Registry study.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
09 2021
Historique:
received: 19 04 2021
accepted: 21 06 2021
pubmed: 3 8 2021
medline: 16 12 2021
entrez: 2 8 2021
Statut: ppublish

Résumé

Among 143 patients with elastase, neutrophil-expressed (ELANE)-related neutropenia enrolled in the French Severe Chronic Neutropenia Registry, 94 were classified as having severe chronic neutropenia (SCN) and 49 with cyclic neutropenia (CyN). Their infectious episodes were classified as severe, mild or oral, and analysed according to their natural occurrence without granulocyte-colony stimulating factor (G-CSF), on G-CSF, after myelodysplasia/acute leukaemia or after haematopoietic stem-cell transplantation. During the disease's natural history period (without G-CSF; 1913 person-years), 302, 957 and 754 severe, mild and oral infectious events, respectively, occurred. Among severe infections, cellulitis (48%) and pneumonia (38%) were the most common. Only 38% of episodes were microbiologically documented. The most frequent pathogens were Staphylococcus aureus (37·4%), Escherichia coli (20%) and Pseudomonas aeruginosa (16%), while fungal infections accounted for 1%. Profound neutropenia (<200/mm

Identifiants

pubmed: 34340247
doi: 10.1111/bjh.17695
doi:

Substances chimiques

ELANE protein, human EC 3.4.21.37
Leukocyte Elastase EC 3.4.21.37

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

908-920

Investigateurs

Elodie Gouache (E)
Fanny Alby-Laurent (F)
Yves Bertrand (Y)
Pierre-Simon Rohrlich (PS)
Eric Jeziorksi (E)
Liana Carausu (L)
Marc Michel (M)
Valérie L T Te (VLT)
Philippe Bensaid (P)
Loïc de Pontual (L)
Louis Terriou (L)
Nicolas Schleinitz (N)
Karima Yakouben (K)
Nizar Mahlaoui (N)
Felipe Suarez (F)
Xavier Delbrel (X)
Dalila Adjaoud (D)
Jean-Louis Stephan (JL)
Guy Leverger (G)
Fanny Fouyssac (F)
Alice Garnier (A)
Chiara Sileo (C)
Aline Moignet (A)
Nathalie Cheikh (N)
Damien Bodet (D)
Eric Dore (E)
Florent Neumann (F)
Fabrice Jardin (F)

Informations de copyright

© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Références

Castagnola E, Rossi MR, Cesaro S, Livadiotti S, Giacchino M, Zanazzo G, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55:1103-7.
Donadieu J, Beaupain B, Fenneteau O, Bellanne-Chantelot C. Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol. 2017;179:557-74.
Donadieu J, Fenneteau O, Beaupain B, Beaufils S, Bellanger F, Mahlaoui N, et al. Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica. 2012;97(9):1312-9.
Bellanne-Chantelot C, Clauin S, Leblanc T, Cassinat B, Rodrigues-Lima F, Beaufils S, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood. 2004;103:4119-25.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the mycoses study group Education and research ronsortium. Clin Infect Dis. 2020;71:1367-76.
Donadieu J, Leblanc T, Bader MB, Barkaoui M, Fenneteau O, Bertrand Y, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45-53.
Rotulo GA, Beaupain B, Rialland F, Paillard C, Nachit O, Galambrun C, et al. HSCT may lower leukemia risk in ELANE neutropenia: a before-after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplant. 2020;55:1614-22.
Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96:2317-22.
Horwitz M, Benson KF, Person RE, Aprikyan AG, Dale DC. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 1999;23:433-6.
Germeshausen M, Deerberg S, Peter Y, Reimer C, Kratz CP, Ballmaier M. The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia. Hum Mutat. 2013;34:905-14.
Makaryan V, Zeidler C, Bolyard AA, Skokowa J, Rodger E, Kelley ML, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol. 2015;22:3-11.
Dinand V, Yadav SP, Bellanne-Chantelot C, Jain S, Bhargava M, Sachdeva A. Hepatic hemangioendothelioma in an infant with severe congenital neutropenia. J Pediatr Hematol Oncol. 2012;34:298-300.
Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006;25:634-9.
Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60:1176-83.
Mirkov I, Popov AA, Lazovic B, Glamoclija J, Kataranovski M. Usefulness of animal models of aspergillosis in studying immunity against Aspergillus infections. J Mycol Med. 2019;29:84-96.
Garg B, Mehta HM, Wang B, Kamel R, Horwitz MS, Corey SJ. Inducible expression of a disease-associated ELANE mutation impairs granulocytic differentiation, without eliciting an unfolded protein response. J Biol Chem. 2020;295:7492-500.
Horwitz MS, Corey SJ, Grimes HL, Tidwell T. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am. 2013;27:19-41.
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010;62:726-59.
Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, et al. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest. 2015;125:3103-16.
Wolach B, Gavrieli R, Wolach O, Stauber T, Abuzaitoun O, Kuperman A, et al. Leucocyte adhesion deficiency-A multicentre national experience. Eur J Clin Invest. 2019;49:e13047.
Adamski Z, Burchardt D, Pawlaczyk-Kamienska T, Borysewicz-Lewicka M, Wyganowska-Swiatkowska M. Diagnosis of Papillon-Lefevre syndrome: review of the literature and a case report. Postepy Dermatol Alergol. 2020;37:671-6.
Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci. 2006;1088:251-64.
Rao S, Yao Y, de Soares BJ, Yao Q, Shen AH, Watkinson RE, et al. Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell. 2021;28:833-45.e5.
Donini M, Fontana S, Savoldi G, Vermi W, Tassone L, Gentili F, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood. 2007;109:4716-23.
Piatosa B, Birbach M, Siewiera K, Ussowicz M, Kalwak K, Drabko K, et al. Significant changes in the composition of the precursor B-cell compartment in children less than 2 years old. Cytometry B Clin Cytom. 2013;84:179-86.
Verhoeven D. Immunometabolism and innate immunity in the context of immunological maturation and respiratory pathogens in young children. J Leukoc Biol. 2019;106:301-8.
Chipeta J, Komada Y, Zhang XL, Deguchi T, Sugiyama K, Azuma E, et al. CD4+ and CD8+ cell cytokine profiles in neonates, older children, and adults: increasing T helper type 1 and T cytotoxic type 1 cell populations with age. Cell Immunol. 1998;183:149-56.
Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573-82.
Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81:2496-502.
Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628-35.

Auteurs

Gioacchino A Rotulo (GA)

Registre des Neutropénies Chroniques, Centre de Référence des Neutropénies Chroniques, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.

Geneviève Plat (G)

Hématologie Oncologie et Immunologie Pédiatrique, Hôpital des Enfants, Toulouse, France.

Blandine Beaupain (B)

Registre des Neutropénies Chroniques, Centre de Référence des Neutropénies Chroniques, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Stéphane Blanche (S)

APHP, UIHR CEREDIH, Hôpital Necker-Enfants Malade, Paris, France.

Despina Moushous (D)

APHP, UIHR CEREDIH, Hôpital Necker-Enfants Malade, Paris, France.

Flore Sicre de Fontbrune (F)

APHP, Service d'Hématologie Transplantation Médullaire, Hôpital Saint-Louis, Paris, France.

Thierry Leblanc (T)

Department of Pediatric Hematology and Immunology, Hôpital Robert-Debré, APHP, Paris, France.

Cécile Renard (C)

Service de Pédiatrie, Institut d'Hématologie et Oncologie Pédiatrique, Centre Hospitalier Universitaire (CHU) de Lyon, Lyon, France.

Vincent Barlogis (V)

Department of Pediatric Hematology, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Marie-Gabrielle Vigue (MG)

Pediatrics, Infectiology, Rhumatology, Hôpital Arnaud-de-Villeneuve, CHRU de Montpellier, Montpellier, France.

Claire Freycon (C)

Service d'Onco-Hématologie Pédiatrique, CHU de Grenoble, Grenoble, France.

Christophe Piguet (C)

Service d'Hémato-Oncologie Pédiatrie, CHU de Limoges, Limoges, France.

Marlène Pasquet (M)

Hématologie Oncologie et Immunologie Pédiatrique, Hôpital des Enfants, Toulouse, France.

Claire Fieschi (C)

Department of Clinical Immunology, Saint-Louis Hospital, APHP, Paris, France.

Wadih Abou-Chahla (W)

Department of Pediatric Hematology, Jeanne-de-Flandre Hospital, CHU de Lille, Lille, France.

Virginie Gandemer (V)

Service d'Hémato-Oncologie Pédiatrique, CHU de Rennes, Rennes, France.

Fanny Rialland (F)

Service d'Oncologie Pédiatrique, CHU de Nantes, Nantes, France.

Frédéric Millot (F)

Service d'Hémato-Oncologie Pédiatrique, CHU de Poitiers, Poitiers, France.

Aude Marie-Cardine (A)

Service d'Hémato-Pédiatrique, CHU de Rouen, Rouen, France.

Catherine Paillard (C)

Service d'Hématologie Oncologie Pédiatrique, CHU de Strasbourg, Strasbourg, France.

Pacifique Levy (P)

Département de Génétique, DMU BioGeM, CHU Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.

Nathalie Aladjidi (N)

Service d'Hémato-Oncologie Pédiatrique, CHU de Bordeaux, Bordeaux, France.

Martin Biosse-Duplan (M)

Service de Médecine Bucco-Dentaire, Hôpital Bretonneau, APHP, Paris, France.

Christine Bellanné-Chantelot (C)

Département de Génétique, DMU BioGeM, CHU Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.

Jean Donadieu (J)

Registre des Neutropénies Chroniques, Centre de Référence des Neutropénies Chroniques, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH